pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$IOVAIOVANCE BIOTHERAPEUTICS, INC.

$IOVA7.3100-2.27%
San Carlos, CA, USupdated 15h ago

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 2: 3Phase 3: 1Marketed: 1
3Phase 21Phase 31Marketed
Marketed
aldesleukin
Metastatic Renal Cell Carcinoma
Phase 3
lifileucel
Metastatic Melanoma
Phase 2
IOV-2001
Chronic Lymphocytic Leukemia (CLL)
Phase 2
IOV-4001
Metastatic Melanoma
Phase 2
LN-145
Non-Small Cell Lung Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 5, 2026
earnings
$IOVA7.3100-2.27%
16d ago
IOVANCE BIOTHERAPEUTICS, INC. earnings
IOVANCE BIOTHERAPEUTICS, INC.
→
view all catalysts →

Active trials

  • phase1Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participantsterminatedn=5
  • phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcomanot yet recruitingn=80
  • phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanomaactive not recruitingn=100
  • —Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Releaseavailable
  • phase2Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancerrecruitingn=170
  • phase3Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.recruitingn=670
  • phase2Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanomacompletedn=220
  • phase1Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLcompletedn=7
🐶 Hiring Signal
36 open roles at IOVANCE BIOTHERAPEUTICS, INC. →

Where IOVANCE BIOTHERAPEUTICS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 36
departmentCommercial 6IT & Engineering 4Clinical 3Market Access 3Medical Affairs 3Finance 2

News

  • Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
    Astellas has struck a deal for Audax Biosciences’ IL-12 program, committing up to $285 million in upfront and option fees to secure a chance to license the preclinical immuno-oncology program.
    fiercebiotech · 23d ago
  • Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
    Eric Cantor, who represented Virginia in the U.S. House of Representatives for 14 years and served as House majority leader from 2011 to 2014, will step up as PhRMA’s next president and CEO on Nov.…
    fiercebiotech · 1mo ago
  • Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing
    Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.
    biopharma_dive · 2mo ago
identifiers
ticker
$IOVA
SEC CIK
0001425205
country
US
source
sec_tickers
top tags
Oncology4NSCLC2
mentioned in
3news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 2m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?